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Abstract
In man, differences in Angiotensin Converting Enzyme (ACE) levels, related to ACE I/D 
genotype, are associated with renal prognosis. This raises the hypothesis that individual 
differences in renal ACE activity are involved in renal susceptibility to inflicted damage. 
Therefore, we studied the predictive effect of renal ACE activity for the severity of renal 
damage induced by a single injection of adriamycin in rats. 
Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by 
renal biopsy in 27 adult male Wistar rats. After one week of recovery, proteinuria was 
induced by adriamycin (1.5 mg/kg i.v. n=18; controls: saline i.v. n=9). Proteinuria was 
measured 2-weekly. After 12 weeks, rats were sacrificed and kidneys harvested.
As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage 
and mild focal glomerulosclerosis. Baseline renal ACE positively correlated with relative 
rise in proteinuria after adriamycin (R=0.62, p≤0.01), renal interstitial α-smooth muscle 
actin (R=0.49, p≤0.05), interstitial macrophage influx (R=0.56, p≤0.05), interstitial 
collagen III (R=0.53, p≤0.05), glomerular α-smooth muscle actin (R=0.74, p≤0.01) and 
glomerular desmin (R=0.48, p≤0.05). Baseline renal ACE did not correlate with focal 
glomerulosclerosis (R=0.22, NS). In controls, no predictive values for renal parameters 
were observed.
Individual differences in renal ACE activity predict the severity of adriamycin-induced 
renal damage in this out-bred rat strain. This supports the assumption that differences 
in renal ACE activity predispose to a less favourable course of renal damage.
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Introduction
Tissue Angiotensin Converting Enzyme 
(ACE) is involved in cardiovascular and 
renal tissue damage [1]. ACE inhibition 
reduces proteinuria and protects against 
progressive renal damage [2,3]. This 
suggests that renal ACE activity might play 
a pathogenic role in the development of 
proteinuria-associated structural renal 
damage.
In man, the I/D polymorphism of the ACE 
gene accounts for half of the variance of 
circulating and tissue ACE levels, with the 
highest ACE levels in DD homozygotes, 
lowest in II homozygotes, and in-between 
values in heterozygotes [4,5]. The D-allele 
of the ACE genotype was reported to be 
associated with worse renal prognosis 
in several renal conditions [6], albeit not 
uniformly so [7,8]. The initiation of renal 
disease, however, does not appear to 
be associated with the D-allele. Based 
on these data, it has been hypothesized 
that genetically determined individual 
differences in renal ACE activity are 
relevant to the extent of renal damage that 
develops in response to injury [9], and 
more specifically, that a higher renal ACE 
activity predisposes to a more progressive 
course of renal damage. In line with this 
assumption, established renal damage 
was associated with elevated renal 
ACE activity in different rat models 
of renal disease [10,11]. These data, 
however, were invariably obtained after 
development of renal damage. Therefore 
they do not allow to identify renal ACE 
as a factor predisposing to renal damage, 
as the elevated ACE activity might just as 
well have been the consequence of renal 
damage. 
To test, therefore, whether higher renal 
ACE activity predisposes to a more 
progressive course of renal damage, we 
prospectively determined renal (and 
plasma) ACE activity in healthy Wistar 
rats prior to induction of nephrosis by 
a single injection of adriamycin, and 
investigated its predictive value for the 
subsequent development of renal damage. 
Adriamycin nephrosis provides a well-
characterized model of progressive renal 
damage, induced by a uniform challenge 
at a single point in time. This results in 
proteinuria and subsequent structural 
renal damage with a relative large 
variability between individual animals. In 
healthy out-bred Wistar rats, the plasma 
and tissue ACE levels display a relatively 
large inter-individual variability, which 
allows testing for the predictive value of 
naturally occurring differences in ACE 
activity. 
Methods
Thirty male Wistar rats (Hsd.Cpb.Wu; 
Harlan Inc, Horst, The Netherlands) 
with an initial weight of 323 (314-332) g 
(median and 95% confidence interval) 
were studied. The animals were housed 
in a temperature-controlled room with 
a 12h light/dark cycle and had free 
access to standard food and tap water. 
Twenty-four hour urine samples were 
collected and food and water intake were 
measured by means of metabolic cages, 
at baseline (prior to renal biopsy), and at 
two week intervals throughout the study. 
One animal died before renal biopsy 
due to complicated orbital puncture and 
one animal the day after biopsy. During 
the course of the experiment, one more 
animal died at week 8. The protocol, as 
described below, was approved by the 
Committee for Animal Experiments of the 
University of Groningen, The Netherlands. 
The study was conducted in accord with 
the NIH Guide for the Care and Use of 
Laboratory Animals.
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Protocols 
After baseline values had been obtained, 
renal biopsy was performed under 
isoflurane/O2/N2 anaesthesia. Tissue was 
resected from the lower pole of the right 
kidney through dorsolateral incision. 
Local haemostasis was obtained by 
application of gel-foam (Spongostan®, 
Ferrosan, Copenhagen, Denmark). The 
median amount of renal tissue removed 
was 0.33 (0.29-0.39) g. Renal tissue was 
further processed for determination of 
ACE activity as described below. During 
the same procedure, blood-samples 
were obtained by orbital puncture for 
determination of plasma ACE activity and 
creatinine.
After one week of recovery from biopsy, 
nephrosis was induced by a single i.v. 
injection of adriamycin under light 
anaesthesia. Nineteen rats received 1.5 
mg/kg adriamycin by tail vein. Nine rats 
serving as controls received saline. 
Twelve weeks after the induction of 
nephrosis, animals were anesthetized 
and blood pressure was measured. 
Subsequently, the abdomen was opened 
through midline incision. A two-ml blood 
sample was obtained via aortic puncture 
for determination of plasma ACE activity 
and creatinine. Kidneys were saline 
perfused and harvested and animals 
were sacrificed. Renal cortical tissue from 
the upper pole was processed for ACE 
determination. Mid-coronal renal tissue 
slices were processed for histological and 
immuno-histochemical examination. 
Measurements 
Urinary protein excretion was measured 
by means of a third generation 
nephelometer (Dade Behring, Mannheim, 
Germany) by using a 20% trichloroacetic 
acid (TCA) solution. Systolic blood 
pressure (SBP) was measured by tail cuff. 
Plasma creatinine level was determined 
colourimetrically (Sigma Chemical Co, St 
Louis, MO, USA).
ACE activity was determined as described 
previously [10]. Renal cortex tissue was 
homogenized in a 50 mM K2PO4 buffer 
at pH 7.5. Subsequently, 100 µl of the 
diluted sample was pipetted into a 0.5 M 
K2PO4 buffer. Then, the substrate (100 µl 
of 12.5 mM Hip-His-Leu [Sigma]) which 
is cleaved by ACE, was added. This was 
incubated at 37 °C for exactly 15 minutes. 
In this amount the substrate is present 
in excess, and thus not rate-limiting 
for the reaction. The conversion of the 
substrate was stopped by adding 1.45 
ml of 280 mM sodiumhydroxide. Then, 
100 µl of 1% phtaldialdehyde, which 
adheres to the formed bipeptid His-Leu, 
was added. The amount of tagged His-
Leu was fluorimetrically determined at 
364 nm excitation wavelength and 486 
nm emission wavelength. This yields 
a measure of the amount of His-Leu 
generated in the sample. In blank samples, 
sodiumhydroxide was added to prevent 
conversion. The substrate was added after 
the incubation period. The coefficient of 
variation was 6% for these measurements 
of ACE activity using this method. 
Histological procedures
Renal tissue was fixed in 4% 
paraformaldehyde and processed for 
paraffin embedding. For morphological 
evaluation, 4 µm sections were cut. One 
series was stained with periodic acid-
Schiff (PAS). Another series was stained 
with polyclonal rabbit anti-rat collagen 
III antibody (Biogenenesis Ltd, Poole, 
UK). An automated staining system was 
used on series for macrophages (ED-
1, Serotec Ltd, Oxford, UK), the pre-
fibrotic markers alpha-smooth muscle 
actin (α-SMA; clone 1A4; Sigma Aldrich, 
St Louis, MO, USA) and desmin (clone 
D33, DAKO Cytomation, Glostrup, 
Denmark). Sections were first dewaxed 
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and subjected to heat induced antigen 
retrieval by overnight incubation in 0.1 
M Tris/HCl buffer at 80°C. Endogenous 
peroxidase was blocked with 0.075% 
H2O2 in phosphate-buffered saline (PBS) 
for 30 minutes. Antibody dilutions were 
made in PBS supplemented with 1% 
bovine serum albumin. Antibody binding 
was detected using sequential incubations 
with peroxidase-labeled rabbit anti-
mouse and peroxidase-labeled goat 
anti-rabbit antibodies (RAMPO/GARPO 
Dakopatts, DAKO). Normal rat serum (1%) 
was added to the secondary antibodies. 
Peroxidase activity developed by using 
3,3-diaminobenzidine tetrachloride for 10 
minutes. 
PAS stained sections were used for 
determination of focal glomerular sclerosis 
(FGS) and mesangial matrix expansion 
(MME). The degree of FGS and MME 
were assessed by scoring 50 glomeruli 
per kidney semi-quantitatively on a scale 
of 0 to 4. FGS was scored positive when 
mesangial matrix expansion and adhesion 
of the glomerular visceral epithelium to 
Bowman’s capsule were present in the 
same segment. If 25% of the glomerulus 
was affected, a score of 1 was adjudged, 
50% was scored as 2, 75% as 3 and 
100% as 4. The ultimate score is obtained 
by multiplying the degree of change by 
the percentage of glomeruli with the 
same degree of injury and adding these 
scores, thus rendering a theoretical range 
of 0 to 200. The number of glomerular 
ED-1 positive cells was determined by 
manual counting of 50 glomeruli per 
kidney. Interstitial macrophage number 
was determined by manual counting of 
30 cortical fields per kidney. 
Interstitial α-SMA and collagen III were 
measured using computer-assisted 
morphometry on 30 cortical fields per 
Adriamycin (n=18) Control (n=9)
Body weight (g) Baseline 320 (318-328) 320 (314-334)
Week 12 461 (448-480)a,c 490 (458-524)c
Biopsy tissue weight (g) 0.33 (0.29-0.40) 0.30 (0.19-0.42)
Kidney weight at termination (g) Left 2.23 (1.97-2.41) 1.92 (1.65-2.29)
Right 1.25 (1.15-1.45) 1.30 (1.00-1.40)
Renal ACE (nmol HL/ml/min) Baseline 56.0 (45.1-70.6) 54.7 (38.7-66.4)
Week 12 47.2 (34.7-59.9) 48.2 (33.9-80.9)
Plasma ACE (nmol HL/ml/min) Baseline 24.7 (21.5-29.2) 29.9 (22.9-34.7)
Week 12 48.3 (44.4-56.2)c 52.1 (39.2-65.4)
Plasma creatinine (mg/l) Baseline 5.1 (4.9-5.5) 5.9 (2.5-6.5)
Week 12 6.0 (5.6-6.3)b 4.9 (4.8-5.3)
Proteinuria (mg/24h) Baseline 31 (17-41) 28 (18-45)
Week 12 268 (148-347)b,c 26 (14-123)
Table 1. Group characteristics from baseline to termination. 
Data are expressed as median and 95% confidence interval of the median; a p<0.05; adriamycin vs. control  
b p<0.01; adriamycin vs. control; c p≤0.01; termination (week 12) vs. baseline.
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kidney, excluding vessels and glomeruli. 
The surface area found positive, was 
divided by the total area of the field 
measured, providing a percentage of 
α-SMA positive tissue. Glomerular α-SMA 
was determined on 50 glomeruli per 
kidney. The glomerular visceral epithelial 
desmin staining was determined by 
manual counting of 50 glomeruli per 
kidney, on a scale of 0 to 100%, with 
intervals of 10%.
Statistical Analysis 
Statistical analyses were performed on 
a total of 27 animals: 18 adriamycin 
animals and 9 controls. The analysis on 
predictive value of endogenous renal 
ACE activity was performed on data 
obtained from the right kidney at biopsy 
and at termination. Left kidneys obtained 
at termination were compared to the 
right kidney termination data to test for 
possible harmful consequences of the 
biopsy. Data are expressed as median 
and 95% confidence interval of the 
median, calculated according to the ranks 
method by Altman. Differences between 
experimental and control groups were 
analysed by Mann-Whitney U test. 
Wilcoxon’s non-parametric test for paired 
samples was used to compare parameters 
from baseline to termination. Pearson’s 
coefficients were calculated to account 
for bivariate correlation. Statistical 
significance was assumed at the 5% level. 




Values for clinical parameters at baseline 
and termination are listed in table 1. 
Food and water intake was similar in 
both groups throughout the experiment. 
Body weight was significantly lower 
in the adriamycin rats as compared to 
controls, from week 8 onwards (p≤0.05, 
data not shown) until termination at week 
12 (p≤0.001). Median systolic blood 
pressure at baseline was 88 mmHg (77-
95) for the two groups together, without 
differences between the groups. At week 
12, blood pressure was slightly higher 
Adriamycin Control
(n=18) (n=9) p-value a
Glomerular mø (per 50 glomeruli) 79 (51-101) 52 (45-71) 0.08
Glomerular α-SMA (mean % of 50 gomeruli) 3.3 (2.0-4.5) 1.8 (1.4-2.0) ≤0.001
Glomerular desmin (mean % of 50 gomeruli) 20 (10-32) 1.6 (0.3-17) ≤0.001
MME score (per 50 glomeruli, scale 0-200) 42 (10-32) 27 (20-44) 0.09
FGS score (per 50 glomeruli, scale 0-200) 19 (6-34) 0 (0-8) ≤0.01
Interstitial mø (per 30 cortical fields) 94 (66-119) 30 (23-42) ≤0.001
Interstitial α-SMA (mean % of 30 fields) 4.2 (3.4-6.8) 2.6 (1.4-4.1) ≤0.05
Interstitial collagen III (mean % of 30 fields) 16.6 (13.5-17.3) 10.5 (8.6-14.9) ≤0.01
Table 2. Structural damage parameters at termination for adriamycin and control animals. 
Data are expressed as median and 95% confidence interval of the median. Abbreviations: mø: macrophage 
count; α-SMA: α-smooth muscle actin; MME: mesangial matrix expansion, FGS: focal glomerular sclerosis.  
a adriamycin vs. control: Mann-Whitney U test.
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in the adriamycin rats as compared to 
controls (134 (125-141) versus 124 (113-
130) mmHg, NS). Subtle proteinuria with 
a median value of 31 (18-40) mg/24h was 
present at baseline. In the adriamycin 
group, proteinuria showed a marked rise 
after adriamycin induction to overtly 
proteinuric values (268 (148-347) versus 
26 (14-123) mg/day in controls at week 12 
(p≤0.001). Plasma creatinine was similar 
in both groups at baseline. At termination, 
plasma creatinine was significantly higher 
in the adriamycin group (p≤0.01). Wet 
kidney weight at termination was similar 
in both groups. 
Structural changes and markers of 
renal damage
Data on structural renal damage at 
termination are shown in table 2. For 
mesangial matrix expansion (MME) 
we found somewhat higher values in 
adriamycin animals, but this difference 
did not reach statistical significance. 
In the adriamycin group, mild focal 
glomerulosclerosis (FGS) was found. 
Macrophage-influx was significantly 
elevated in the adriamycin group as 
compared to control, both for interstitial 
and glomerular macrophages. Both 
interstitial and glomerular α-SMA 
expression and glomerular epithelial 
desmin expression were significantly 
increased in the adriamycin group. 
Interstitial collagen III expression was 
significantly elevated in adriamycin 
animals. All immunohistological 
parameters at termination were similar 
for left and right kidney in both groups, 
indicating that these parameters were not 
affected by the prior renal biopsy (data 
not shown). 
Predictive value for adriamycin-
induced renal damage
Baseline renal ACE activity significantly 
correlated with the rise in proteinuria 
induced by adriamycin [figure 1]. 
Bivariate correlations between baseline 
renal ACE activity and renal damage at 
termination in the adriamycin rats are 
given in figure 2. It shows that baseline 
renal ACE activity correlated positively 
and significantly with the expression of 
glomerular markers α-SMA and desmin 
and with interstitial α-SMA and collagen III 
expression in adriamycin rats. Renal ACE 
activity at baseline predicted interstitial 
macrophage influx at termination as well 
(R=0.56; p≤0.05). Glomerular macrophage 
count (R=0.13; p=0.62), MME and FGS 
did not correlate with baseline renal ACE 
activity (R=0.33; p=0.18 and R=0.22; 
p=0.37, respectively). Plasma ACE values 
at baseline had no predictive effect for 
any of the renal parameters. In control 
animals, neither renal nor plasma ACE 
had a predictive effect for any of the renal 
parameters. 
On cross-sectional analysis of termination 
data in adriamycin animals, renal ACE 
activity at termination significantly 
correlated with FGS (R=0.61), interstitial 
macrophages (R=0.57), interstitial 
α-SMA (R=0.65), glomerular desmin 
(R=0.72), glomerular α-SMA (R=0.75) and 
proteinuria (R=0.68; all p≤0.01) but again 
Figure 1. The predictive value of baseline 
renal ACE activity for the percentage change 
in adriamycin induced proteinuria.
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not with glomerular macrophage influx 
(R=0.07; p=0.77). For collagen III and 
MME the correlations were of borderline 
significance (R=0.47; p=0.05 and R=0.49; 
p=0.06, respectively). All parameters for 
renal damage at termination correlated 
with week 12 proteinuria (data not 
shown).
Finally, the between-individual differences 
in renal and plasma ACE activity were 
consistent between the start and the end 
of the study. This is illustrated in figure 3, 
providing the correlation between renal 
ACE at baseline and at termination (upper 
panel) and the correlation between plasma 
ACE at baseline and at termination (lower 
panel, n=16 for adriamycin and n=8 for 
control animals).
Discussion
Individual differences in renal, but not 
plasma, ACE activity predicted the rise 
in proteinuria induced by adriamycin, the 
severity of renal interstitial changes and 
the expression of the glomerular markers 
α-SMA and desmin. This supports the 
hypothesis that individual differences 
in renal ACE level are relevant to the 
progression of renal damage. 
The differences in baseline renal ACE 
activity can be considered to reflect 
naturally occurring differences between 
these out-bred animals. Interestingly, 
in these adriamycin rats, the between-
individual differences found at baseline 
were consistent throughout the study from 
the pre-induction values in normal kidney 
Figure 2. Predictive value of baseline renal ACE activity for renal damage. 
Parameters for renal damage are glomerular a-SMA, glomerular desmin, interstitial a-SMA and interstitial col-
lagen III, respectively. Data shown are for adriamycin animals. 
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trough the termination values in diseased 
kidney. This consistency strongly suggests 
that the values reflect a true difference 
between the animals rather than a random 
fluctuation at the time of biopsy. 
It could be argued that the renal biopsy 
affected the renal outcome in our 
study. However, no morphological 
or immunohistochemical differences 
between the biopsied and the non-
biopsied kidney were found at 
termination. Renal ACE activity at 
termination was similar in biopsied 
kidney compared to non-biopsied kidney. 
Thus, whereas effects of the renal biopsy 
cannot be excluded, they do not modify 
the conclusions of our study.
In the time-controls, median proteinuria 
was low and stable throughout the 
study, and values at termination were not 
predicted by baseline ACE. Considering 
the absence of substantial abnormalities 
at termination in these animals, the 
likelihood to detect a predictive effect 
within the time frame of the study was 
low. It would be of interest, therefore, 
to study long-term age-related changes 
in this strain in relation to baseline renal 
ACE activity. 
Baseline renal ACE predicted the severity 
of interstitial and glomerular prefibrotic 
changes, but not focal glomerular sclerosis 
and MME. Within the timeframe of our 
study, the glomerular sclerotic changes, 
however, remained mild. Accordingly, 
the quantitative resolution to detect a 
relationship with the glomerular sclerotic 
changes may have been too limited. 
The predictive value of renal ACE for 
expression of the pre-fibrotic glomerular 
markers suggests, that a consistent 
dissociation between interstitial and 
glomerular changes is unlikely. In this 
model interstitial morphological changes 
have been noted to prevail over glomerular 
changes [11]. Nevertheless, during 
advanced stages of renal damage in this 
model, usually interstitial and glomerular 
changes go hand in hand [12]. Therefore, 
it would be worthwhile to investigate 
whether during long-term follow-up, 
baseline ACE predicts the progression of 
glomerular sclerosis as well. 
Figure 3. The correlation between baseline ACE activity with termination ACE activity for 
adriamycin and control animals.
Closed circles and continuous lines represent control animals. Open circles and dashed lines represent adriamycin 
animals. Left panel (renal ACE): R=0.46 for control (NS) and R=0.59 for adriamycin animals (p<0.01). Right panel 
(plasma ACE): R=0.79 for control and R=0.59 for adriamycin animals (both p<0.05).
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Our data show the predictive value of 
baseline ACE for renal damage but do 
not provide proof for a causal role of 
renal ACE activity in the differences in 
renal damage, as we cannot exclude that 
it is an epiphenomenon to –unknown– 
associated factors. Study designs with 
intervention in renal ACE activity, either 
pharmacological or genetic, would 
be needed for conclusive proof. The 
renoprotective effect of ACE-inhibition in 
this model, as well as other proteinuric 
models [2;13-17] is well-established, and 
in line with a role of renal ACE in renal 
damage, albeit not conclusively, as the 
relationship between baseline renal ACE 
and pharmacodynamics of ACE-inhibition 
is complicated, and has not been well-
characterized. 
Recent data in mice with extra copies of 
the ACE gene provided specific data on 
this issue. These genetically engineered 
mice have modestly elevated plasma 
ACE and kidney ACE mRNA, but do not 
develop spontaneous renal damage. After 
induction of diabetes, they develop more 
severe hypertension and renal damage 
than animals with one or two copies [18]. 
Thus, a genetically elevated ACE activity 
does not elicit renal damage, but when 
damage is inflicted, the course is more 
severe, which is well in line with our data 
in out-bred rats. 
By what mechanism could renal ACE 
activity modify the course of renal 
damage? Egido’s group [19] postulated 
that elevated ACE activity in tubular and 
interstitial cells leads to generation of 
angiotensin II, which contributes to tubulo-
interstitial damage by its pro-inflammatory 
and pre-fibrotic effects. In experimental 
renal disease (protein-overload) and 
human diabetic nephropathy [20], these 
authors found higher renal ACE activity 
when renal damage was present. This is 
in line with a prior study from our group 
in adriamycin nephrosis [21]. These data 
were obtained after development of renal 
damage, however. The higher renal ACE 
in association with more severe damage 
might be the result from renal damage, 
rather than a predisposing factor. Our 
present data show that individual renal 
ACE levels in the healthy condition 
precede, and thus predict the course of 
renal damage. Moreover, the predictive 
value was observed despite stable renal 
ACE levels throughout the study, showing 
that the predictive effect of baseline 
renal ACE does not depend on a disease-
associated rise in renal ACE level. The 
absence of a rise in renal ACE activity in 
our study is somewhat at variance with 
increased renal ACE activity in some 
other studies [19]. This may be due to 
differences between the models, or to the 
relatively mild extent of damage in our 
study. 
In conclusion, our data show that naturally 
occurring individual differences in renal 
ACE levels predict the susceptibility to 
adriamycin-induced renal injury. This 
suggests that differences in renal ACE 
activity predispose to a more aggressive 
course of renal damage. Future studies 
are needed to investigate the underlying 
mechanisms, and to explore whether this 
predictive effect also applies to other 
models of renal damage and in human 
renal disease.
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